In a nutshell This study evaluated the effectiveness and safety of elacestrant (RAD1901) versus standard hormonal therapy in patients with estrogen receptor-positive (ER+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that elacestrant significantly improved survival without cancer worsening with manageable side effects in these...
Read More
In a nutshell This review looked at whether women who used fertility medications more often developed breast cancer later on. It found that women treated with ovarian stimulation had similar rates of breast cancer to other women. Some background Treatment for infertility has become common, both as people have children later, and as the condition is...
Read More
In a nutshell This phase 2 trial will evaluate the safety and effectiveness of ribociclib (Kisqali) combined with hormonal therapy in patients with estrogen receptor-positive (ER+) breast cancer (BC). The main outcome will be the number of patients that complete 1 year of treatment and survival without signs of cancer. The trial will...
Read More
In a nutshell This phase 2 trial will investigate the safety of durvalumab (Imfinzi) in combination with standard hormonal treatment for breast cancer (BC). The main outcome will be the response to treatment. The trial is recruiting in Tampa, Florida, US. The details Breast cancer (BC) is one of the most common cancers. It affects bothe...
Read More
In a nutshell This paper compared the location of triple-negative breast cancer with estrogen receptor positive breast cancer using magnetic resonance imaging (type of scan). Some background Studies have shown that the location of cancer could affect its growth. The location of cancer can also be used to predict the outcome in patients....
Read More
In a nutshell This paper studied whether palbociclib (Ibrance) used in combination with letrozole (Femara) benefits breast cancer patients who are estrogen receptor positive (presence of receptor on cells) and human epidermal growth factor receptor 2 negative (absence of receptor on cells). Some background Estrogen receptor and human...
Read More
In a nutshell This paper evaluated the safety and effectiveness of fulvestrant (Faslodex) in men with breast cancer. Some background Male breast cancer is uncommon, and hence there are a lack of clinical trials and treatment recommendations specifically for men. While tamoxifen (Soltamox, Nolvadex) is regarded as the gold standard of adjuvant...
Read More
In a nutshell This study examined overall survival rates following treatment with different dosages of fulvestrant (Faslodex) in patients with recurrent or metastatic estrogen receptor-positive breast cancer. Some background Estrogen receptor-positive (ER+) breast cancers are dependent on the hormone estrogen for continued growth and spread....
Read More
